LEWIS JUDD JOINS ROCHE BIOSCIENCE SCIENTIFIC ADVISORY BOARD
Palo Alto, Calif., May 17, 2001 – Roche Bioscience in Palo Alto has named Lewis Judd, M.D., Mary Gilman Marston Professor and chair of the Department of Psychiatry for the University of California, San Diego School of Medicine, as the newest member of its scientific advisory board.
Judd holds a B.S. degree from the University of Utah and an M.D. from the UCLA School of Medicine. He completed his residency in UCLA's Department of Psychiatry. Judd is the former director of the National Institute of Mental Health (NIMH) in Washington, D.C. "We are extremely pleased that Lewis Judd has agreed to serve on our scientific advisory board," said James Woody, M.D., Ph.D., president, Roche Bioscience. "We will look to him to challenge us and provide valuable expertise as an advisor on early-stage central nervous system (CNS) research programs in depression, schizophrenia and other neuropsychiatric diseases that are underway here," said Dr. Woody. CNS is an emerging research area for Roche Bioscience.
The Roche Bioscience advisory board is comprised of internationally-recognized scientists with research and clinical expertise in areas including neurobiology and immunology. The advisors review early research programs and provide critical evaluations and advice from an academic perspective.
The next advisory board meeting will take place in Palo Alto from May 24-25.
In addition to Judd, the board includes:
- John Bell, M.D., D.Phil., Clinical Immunology and Genetics, Oxford
- Leslie Z. Benet, Ph.D., professor and chair of biopharmaceutical sciences, University of California at San Francisco School of Pharmacy
- E.J. Corey, Ph.D., Chemistry, Harvard University, Cambridge, Mass.
- Marc Feldmann, M.D., Ph.D., Kennedy Institute of Rheumatology, Sunley Division, England
- Larry Steinmann, M.D., professor of neurology at the Stanford University Medical Center
- Greg L. Verdine, Ph.D., professor of chemical biology at Harvard University
About Roche
The Roche pharmaceutical operations in Palo Alto include Roche Bioscience and Roche Global Development. Roche Bioscience is focused on the discovery and early clinical development of innovative new medicines to treat diseases including arthritis, asthma and other respiratory diseases; depression, schizophrenia and other neuropsychiatric diseases; genitourinary diseases and osteoporosis. The Roche Global Development organization in Palo Alto manages human clinical studies and works to achieve worldwide regulatory approvals for compounds from the Roche research pipeline.
Located in the Stanford Research Park, Roche employs approximately 1,200 men and women in Palo Alto as part of the Roche Group. Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative services address the prevention, diagnosis and treatment of diseases, thus enhancing people's well-being and quality of life.
More information about the Roche campus in Palo Alto is available at http://paloalto.roche.com
